| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jayashri Kulkarni, Adam De Chellis, Heather Gilbert, Emmy Gavrilidis, Eveline Mu, Leila Karimi, Qi L. Clozapine Safety in Pregnancy: A Clinical Study. Schizophrenia bulletin. 2024-07-20. PMID:39031964. |
pregnant women with persistent schizophrenia and related disorders may require ongoing antipsychotic treatment, including clozapine. |
2024-07-20 |
2024-07-24 |
Not clear |
| Rommy Cedeno, Arturo P Jaramillo, Ahmad R Kha. Comparative Effectiveness of Amisulpride and Clozapine in the Treatment of Schizophrenia: A Systematic Review and Meta-Analysis. Cureus. vol 16. issue 6. 2024-07-19. PMID:39027775. |
comparative effectiveness of amisulpride and clozapine in the treatment of schizophrenia: a systematic review and meta-analysis. |
2024-07-19 |
2024-07-21 |
Not clear |
| Hans Joachim de Haas, Dan Cohen, Mariken Beatrijs de Koning, Geke van Weringh, Veroljub Petrovic, Lieuwe de Haan, Daan Johannes Touw, Dragana Ignjatovic Risti. Clozapine levels and outcomes in Serbian patients with treatment-resistant psychotic disorders previously treated without measuring clozapine levels (CLOSER). Psychiatry research. vol 339. 2024-07-19. PMID:39029392. |
clozapine remains the only pharmacological treatment option for treatment-resistant schizophrenia. |
2024-07-19 |
2024-07-22 |
Not clear |
| Lizhi Zhang, Yiying Zhou, Yanhong Xie, Yudong Ying, Yan Li, Sen Ye, Zhengchun Wan. Adjunctive clozapine with bright light mitigates cognitive deficits by synaptic plasticity and neurogenesis in sub-chronic MK-801 treated mice. Pharmacology, biochemistry, and behavior. 2024-07-13. PMID:39002805. |
schizophrenia impacts about 1 % of the global population, with clozapine (clz) being a critical treatment for refractory cases despite its limitations in effectiveness and adverse effects. |
2024-07-13 |
2024-07-16 |
mouse |
| Lingyan Qi, Botao Ma, Hongzhen Fan, Siyuan Qi, Fude Yang, Huimei A. Case report: Time response of plasma clozapine concentrations on cessation of heavy smoking. Frontiers in pharmacology. vol 15. 2024-07-08. PMID:38974031. |
this case report investigated the trajectory of clozapine plasma concentrations over time after smoking cessation in a chinese inpatient with schizophrenia. |
2024-07-08 |
2024-07-11 |
Not clear |
| Lingyan Qi, Botao Ma, Hongzhen Fan, Siyuan Qi, Fude Yang, Huimei A. Case report: Time response of plasma clozapine concentrations on cessation of heavy smoking. Frontiers in pharmacology. vol 15. 2024-07-08. PMID:38974031. |
this case report delineates the temporal response of plasma clozapine concentrations and dose-corrected clozapine plasma concentrations in a 33-year-old inpatient with schizophrenia who had a substantial smoking history and ceased smoking abruptly during dose titration. |
2024-07-08 |
2024-07-11 |
Not clear |
| Rikuto Christopher Shinohara, Tomomi Oshima, Takafumi Otsubo, Keita Ariga, Tesshu Ono, Koya Muneoka, Hiroki Umezu, Nobuhiro Mikam. Successful utilization of clozapine for a patient with treatment-resistant schizophrenia after recurrent violent behavior. Neuropsychopharmacology reports. 2024-07-04. PMID:38961521. |
successful utilization of clozapine for a patient with treatment-resistant schizophrenia after recurrent violent behavior. |
2024-07-04 |
2024-07-10 |
Not clear |
| Júlio César Menezes Vieira, Edna Afonso Reis, Augusto Afonso Guerra, Helian Nunes de Oliveira, Cristina Mariano Rua. Comparative effectiveness of clozapine and non-clozapine atypical antipsychotics provided by the Brazilian National Health System in adults with schizophrenia. Frontiers in psychiatry. vol 15. 2024-07-04. PMID:38962057. |
comparative effectiveness of clozapine and non-clozapine atypical antipsychotics provided by the brazilian national health system in adults with schizophrenia. |
2024-07-04 |
2024-07-10 |
Not clear |
| Júlio César Menezes Vieira, Edna Afonso Reis, Augusto Afonso Guerra, Helian Nunes de Oliveira, Cristina Mariano Rua. Comparative effectiveness of clozapine and non-clozapine atypical antipsychotics provided by the Brazilian National Health System in adults with schizophrenia. Frontiers in psychiatry. vol 15. 2024-07-04. PMID:38962057. |
we aimed to assess the survival of patients with schizophrenia using clozapine compared with non-clozapine atypical antipsychotics provided by the brazilian national health system using real-world data. |
2024-07-04 |
2024-07-10 |
Not clear |
| Sandeep Grover, Arshia Sood, Subho Chakrabart. Use of Clozapine in persons with a history of seizures: A retrospective study. Asian journal of psychiatry. vol 98. 2024-07-02. PMID:38955034. |
seizures are considered to be one of the dreaded side effects of clozapine, and due to this, the use of clozapine is avoided in patients with treatment-resistant schizophrenia. |
2024-07-02 |
2024-07-06 |
Not clear |
| S Nath, S K Padhy, S Kumar. Ivabradine-induced delirium in a patient taking clozapine for treatment-resistant schizophrenia: a case report. East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan. vol 34. issue 1. 2024-07-02. PMID:38955780. |
ivabradine-induced delirium in a patient taking clozapine for treatment-resistant schizophrenia: a case report. |
2024-07-02 |
2024-07-06 |
Not clear |
| Mishal Qubad, Gabriele Dupont, Martina Hahn, Simon S Martin, Valentina Puntmann, Eike Nagel, Andreas Reif, Robert A Bittne. When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis. CNS drugs. 2024-07-01. PMID:38951464. |
when, why and how to re-challenge clozapine in schizophrenia following myocarditis. |
2024-07-01 |
2024-07-04 |
Not clear |
| Mishal Qubad, Gabriele Dupont, Martina Hahn, Simon S Martin, Valentina Puntmann, Eike Nagel, Andreas Reif, Robert A Bittne. When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis. CNS drugs. 2024-07-01. PMID:38951464. |
clozapine-induced myocarditis (cim) is among the most important adverse events limiting the use of clozapine as the most effective treatment for schizophrenia. |
2024-07-01 |
2024-07-04 |
Not clear |
| Ali Alalawi, Enas Albalawi, Abdullah Aljohani, Abdullah Almutairi, Abdulraouf Alrehili, Areej Albalawi, Ahmed Aldhafir. Decoding Clozapine-Induced Agranulocytosis: Unraveling Interactions and Mitigation Strategies. Pharmacy (Basel, Switzerland). vol 12. issue 3. 2024-06-26. PMID:38921968. |
clozapine is an antipsychotic medication that has demonstrated substantial efficacy in remediating refractory schizophrenia and various other psychiatric disorders. |
2024-06-26 |
2024-06-29 |
Not clear |
| Anton Freibüchler, Roland Seifer. Analysis of clinical studies on clozapine from 2012-2022. Naunyn-Schmiedeberg's archives of pharmacology. 2024-06-25. PMID:38918233. |
clozapine has been considered the "gold standard" in the treatment of schizophrenia for many years. |
2024-06-25 |
2024-06-29 |
Not clear |
| Anton Freibüchler, Roland Seifer. Analysis of clinical studies on clozapine from 2012-2022. Naunyn-Schmiedeberg's archives of pharmacology. 2024-06-25. PMID:38918233. |
however, due to its numerous adverse reactions, clozapine is mainly used for treatment-resistant schizophrenia. |
2024-06-25 |
2024-06-29 |
Not clear |
| Anton Freibüchler, Roland Seifer. Analysis of clinical studies on clozapine from 2012-2022. Naunyn-Schmiedeberg's archives of pharmacology. 2024-06-25. PMID:38918233. |
no investigated drug was superior to clozapine for the treatment of schizophrenia. |
2024-06-25 |
2024-06-29 |
Not clear |
| Edgardo Torres-Carmona, Shinichiro Nakajima, Yusuke Iwata, Fumihiko Ueno, Cristiana Stefan, Jianmeng Song, Ali Abdolizadeh, Michel Teruki Koizumi, Yasaman Kambari, Aron Amaev, Sri Mahavir Agarwal, Wanna Mar, Vincenzo de Luca, Gary Remington, Philip Gerretsen, Ariel Graff-Guerrer. Clozapine treatment and astrocyte activity in treatment resistant schizophrenia: A proton magnetic resonance spectroscopy study. Schizophrenia research. vol 270. 2024-06-23. PMID:38909486. |
clozapine treatment and astrocyte activity in treatment resistant schizophrenia: a proton magnetic resonance spectroscopy study. |
2024-06-23 |
2024-06-26 |
human |
| Edgardo Torres-Carmona, Shinichiro Nakajima, Yusuke Iwata, Fumihiko Ueno, Cristiana Stefan, Jianmeng Song, Ali Abdolizadeh, Michel Teruki Koizumi, Yasaman Kambari, Aron Amaev, Sri Mahavir Agarwal, Wanna Mar, Vincenzo de Luca, Gary Remington, Philip Gerretsen, Ariel Graff-Guerrer. Clozapine treatment and astrocyte activity in treatment resistant schizophrenia: A proton magnetic resonance spectroscopy study. Schizophrenia research. vol 270. 2024-06-23. PMID:38909486. |
clozapine is the only antipsychotic approved for treating treatment-resistant schizophrenia (trs), characterized by persistent positive symptoms despite adequate antipsychotic treatment. |
2024-06-23 |
2024-06-26 |
human |
| Fumihiko Kawai, Satsuki Watanabe, Hirotaka Ebihara, Naoki Shimizu, Shiori Oshima, Hiroshi Okai, Yoshiko Murata, Hisatoshi Arai, Koji Matsu. Recurrent reactive hypoglycemia due to clozapine-induced glucose intolerance: A case report. PCN reports : psychiatry and clinical neurosciences. vol 2. issue 4. 2024-06-13. PMID:38868726. |
although diabetes is one of the most common side effects of clozapine, a medication for the treatment of schizophrenia, to the best of our knowledge no study exists on clozapine-induced glucose intolerance or hypoglycemia in patients with schizophrenia. |
2024-06-13 |
2024-06-15 |
Not clear |